Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Afizagabar - Servier

Drug Profile

Afizagabar - Servier

Alternative Names: S-44819

Latest Information Update: 09 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Servier
  • Class Benzodiazepinones; Oxazoles; Small molecules; Vascular disorder therapies
  • Mechanism of Action GABA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Stroke

Most Recent Events

  • 09 Aug 2019 Chemical structure information added
  • 29 May 2019 Discontinued - Phase-II for Stroke (In the elderly, In adults) in Canada, Spain, Brazil, France, Italy, Poland, Czech Republic, Netherlands, South Korea, Hungary, Belgium, Germany (PO), United Kingdom, Australia, Sweden (PO) due to negative results from phase II trial
  • 04 Apr 2019 Servier completes the phase II EMPOWER BRAIN trial in Stroke in United Kingdom, Sweden, Spain, Poland, Netherlands, Hungary, Germany, Belgium, Australia, France, South Korea, Italy, Canada, Czech Republi and Brazil (NCT02877615)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top